Translational Pharmaceutics® for First-in-Human Studies

Quotient Sciences’ Translational Pharmaceutics® platform enables First-in-Human (FIH) studies by re-engineering the transition of your drug molecule into clinical development and optimising the timeline to Proof-of-Concept (POC). Translational Pharmaceutics® is applicable to all drug molecules, routes of delivery, and formulations.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sections

Sections

Sections

Sections

Sections

Sections

Translational Pharmaceutics® for First-in-Human Studies

Phase I/Clinical Pharmacology: Exploratory and Regulatory-Driven Studies

FIH to POC: The Journey from Bench to Patient

Drug Product Development and Manufacturing Services

Quotient Sciences Corporate Overview

Clinical Pharmacology Services